Sicart Associates LLC Sells 4,200 Shares of Gilead Sciences, Inc. (NASDAQ:GILD)

Sicart Associates LLC decreased its position in Gilead Sciences, Inc. (NASDAQ:GILD - Free Report) by 3.8% in the 4th quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The institutional investor owned 105,930 shares of the biopharmaceutical company's stock after selling 4,200 shares during the period. Gilead Sciences comprises approximately 3.5% of Sicart Associates LLC's holdings, making the stock its 6th largest holding. Sicart Associates LLC's holdings in Gilead Sciences were worth $9,785,000 at the end of the most recent reporting period.

Several other institutional investors also recently modified their holdings of the company. Mirador Capital Partners LP raised its position in Gilead Sciences by 4.0% in the fourth quarter. Mirador Capital Partners LP now owns 13,723 shares of the biopharmaceutical company's stock worth $1,268,000 after purchasing an additional 528 shares in the last quarter. USA Financial Formulas acquired a new position in shares of Gilead Sciences in the 4th quarter worth approximately $1,539,000. BluePath Capital Management LLC lifted its position in shares of Gilead Sciences by 15.2% during the 4th quarter. BluePath Capital Management LLC now owns 9,854 shares of the biopharmaceutical company's stock worth $886,000 after buying an additional 1,299 shares during the period. Armstrong Advisory Group Inc. boosted its stake in Gilead Sciences by 14.2% in the 4th quarter. Armstrong Advisory Group Inc. now owns 1,606 shares of the biopharmaceutical company's stock valued at $148,000 after buying an additional 200 shares in the last quarter. Finally, Park Avenue Securities LLC grew its position in Gilead Sciences by 31.4% in the fourth quarter. Park Avenue Securities LLC now owns 28,753 shares of the biopharmaceutical company's stock valued at $2,656,000 after acquiring an additional 6,878 shares during the period. Institutional investors and hedge funds own 83.67% of the company's stock.

Insider Activity at Gilead Sciences

In related news, Director Jeffrey Bluestone sold 6,788 shares of Gilead Sciences stock in a transaction that occurred on Tuesday, November 26th. The stock was sold at an average price of $91.39, for a total value of $620,355.32. Following the sale, the director now owns 8,920 shares of the company's stock, valued at approximately $815,198.80. This trade represents a 43.21 % decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, CFO Andrew D. Dickinson sold 248,645 shares of the company's stock in a transaction that occurred on Friday, November 29th. The stock was sold at an average price of $92.76, for a total value of $23,064,310.20. Following the transaction, the chief financial officer now directly owns 138,919 shares of the company's stock, valued at approximately $12,886,126.44. This trade represents a 64.16 % decrease in their position. The disclosure for this sale can be found here. In the last ninety days, insiders have sold 456,234 shares of company stock valued at $42,130,461. 0.29% of the stock is owned by corporate insiders.

Wall Street Analysts Forecast Growth

A number of brokerages have issued reports on GILD. The Goldman Sachs Group lifted their price objective on Gilead Sciences from $74.00 to $84.00 and gave the company a "neutral" rating in a report on Thursday, November 7th. Needham & Company LLC reiterated a "hold" rating on shares of Gilead Sciences in a research report on Thursday, November 7th. Oppenheimer increased their target price on Gilead Sciences from $105.00 to $115.00 and gave the stock an "outperform" rating in a report on Tuesday, December 10th. Sanford C. Bernstein assumed coverage on Gilead Sciences in a report on Thursday, October 17th. They issued an "outperform" rating and a $105.00 price target for the company. Finally, BMO Capital Markets increased their price objective on shares of Gilead Sciences from $94.00 to $102.00 and gave the stock an "outperform" rating in a report on Thursday, November 7th. Eleven analysts have rated the stock with a hold rating, thirteen have issued a buy rating and four have given a strong buy rating to the company. According to data from MarketBeat, Gilead Sciences presently has an average rating of "Moderate Buy" and an average price target of $97.96.

Gilead Sciences Trading Up 0.2 %

GILD stock traded up $0.19 during midday trading on Friday, hitting $91.84. 6,852,085 shares of the company's stock were exchanged, compared to its average volume of 6,737,253. Gilead Sciences, Inc. has a one year low of $62.07 and a one year high of $98.90. The company has a debt-to-equity ratio of 1.24, a quick ratio of 1.10 and a current ratio of 1.26. The company has a market cap of $114.46 billion, a PE ratio of 1,020.44, a price-to-earnings-growth ratio of 1.27 and a beta of 0.18. The stock's fifty day moving average price is $91.85 and its 200-day moving average price is $83.81.

Gilead Sciences (NASDAQ:GILD - Get Free Report) last released its quarterly earnings data on Wednesday, November 6th. The biopharmaceutical company reported $2.02 earnings per share for the quarter, beating the consensus estimate of $1.58 by $0.44. Gilead Sciences had a return on equity of 29.00% and a net margin of 0.45%. The business had revenue of $7.55 billion for the quarter, compared to analysts' expectations of $7.01 billion. During the same quarter in the previous year, the business posted $2.29 EPS. Gilead Sciences's revenue for the quarter was up 7.0% on a year-over-year basis. Research analysts predict that Gilead Sciences, Inc. will post 4.36 earnings per share for the current fiscal year.

Gilead Sciences Dividend Announcement

The business also recently disclosed a quarterly dividend, which was paid on Monday, December 30th. Stockholders of record on Friday, December 13th were given a dividend of $0.77 per share. This represents a $3.08 annualized dividend and a dividend yield of 3.35%. The ex-dividend date was Friday, December 13th. Gilead Sciences's dividend payout ratio is 3,422.22%.

Gilead Sciences Company Profile

Gilead Sciences, Inc, a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, Sunlencs, and Atripla products for the treatment of HIV/AIDS; Veklury, an injection for intravenous use, for the treatment of COVID-19; and Epclusa, Harvoni, Vemlidy, and Viread for the treatment of viral hepatitis.